Five-membered heterocycles useful as serine protease inhibitors

Details Five-membered heterocycles useful as serine protease inhibitors Five-membered heterocycles useful as serine protease inhibitors

2005-06-13

2008-11-18

Stockton, Laura L. (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S397000

Reexamination Certificate

active

07453002

ABSTRACT:
The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V):or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, R4, R6, R11, X1, X2, and X3are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.

REFERENCES:
patent: 6069162 (2000-05-01), Itoh et al.
patent: 6518292 (2003-02-01), Robl et al.
patent: 2002/0010140 (2002-01-01), Striker
patent: 2003/0232875 (2003-12-01), Bartlett et al.
patent: 2004/0186151 (2004-09-01), Mjalli et al.
patent: 2004/0220206 (2004-11-01), Smallheer et al.
patent: 2004/0235847 (2004-11-01), Quan et al.
patent: 2006/0009455 (2006-01-01), Corte et al.
patent: 2006/0154915 (2006-07-01), Corte et al.
patent: WO96/16080 (1996-05-01), None
patent: WO 9745425 (1997-12-01), None
patent: WO 9827108 (1998-06-01), None
patent: WO 9964401 (1999-12-01), None
patent: WO00/00477 (2000-01-01), None
patent: WO 0025768 (2000-05-01), None
patent: WO 0126656 (2001-04-01), None
patent: WO 0127079 (2001-04-01), None
patent: WO01/32615 (2001-05-01), None
patent: WO01/32628 (2001-05-01), None
patent: WO01/51487 (2001-07-01), None
patent: WO-01/62756 (2001-08-01), None
patent: WO-01/66539 (2001-09-01), None
patent: WO02/10140 (2002-02-01), None
patent: WO 02069965 (2002-09-01), None
patent: WO03/000180 (2003-01-01), None
patent: WO03/035615 (2003-05-01), None
patent: WO03/076432 (2003-09-01), None
patent: WO 2004011445 (2004-02-01), None
patent: WO2004/085439 (2004-03-01), None
patent: WO2004/056784 (2004-07-01), None
patent: WO 2004071448 (2004-08-01), None
patent: WO2004/101555 (2004-11-01), None
patent: WO2005/035510 (2005-04-01), None
patent: WO2005/056550 (2005-06-01), None
patent: WO2005/061496 (2005-07-01), None
patent: WO2005/082895 (2005-09-01), None
Souillac, et al., Characterization of Delivery Systems, Differential Scanning Calorimetry in Encyclopedia of Controlled Drug Delivery, 1999, John Wiley & Sons, pp. 212-227.
Vippagunta et al., Advanced Drug Delivery Reviews, 48 (2001), pp. 3-26.
U.S. Appl. No. 11/151,627, filed Jun. 13, 2005, Corte et al.
Crawford et al., “The Preparation of Benziminazoles from α-Benzamido-acids and Peptides”,J. Chem. Soc., pp. 673-675, 1956.
Kilburn et al., “Solid-phase synthesis of substituted 2-aminomethylbenzimidazoles”,Tetrahedron Letters, vol. 41, pp. 5419-5421, 2000.
Pantano et al., “Structural Versatility of Peptides from Cαα-Disubstituted Glycines. Synthesis, Characterization, and Solution Conformational Analysis of Homopeptides from Cα-Methyl-Cα-benzylglycine, [(α-Me)Phe]n1”,Macromolecules, vol. 26, pp. 1980-1984, 1993.
Meanwell, et al., “Nonprostanoid Prostacyclin Mimetics. 5. Structure-Activity Relationships Associated with [3-[4-(4,5-Diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic Acid”,J. Med. Chem., vol. 36, pp. 3884-3903, 1993.
Galiani, D., “Activation of Factor IX by Factor Xla”,Trends in Cardiovascular Medicine, vol. 10, No. 5; 2000, pp. 198-204.
Bouma, B.N. et al., “Thrombin-Activatable Fibrinolysis Inhibitor (TAFI, Plasma Procarboxypeptidase B, Procarboxypeptidase R, Procarboxypeptidase U)”,Thrombosis. Research, 2001, 101, pp. 329-354.
Gailani, D., “Gene Targeting in Hemostasis. Factor XI”,Frontiers in Bioscience, 2001, 6, pp. d201-d207.
Gailani, D., et al., “A murine model of factor XI deficiency”,Blood Coagulation and Fibrinolysis, 1997, vol. 8, pp. 134-144.
Minnema, M.C., et al., “Activation of Clotting Factors XI and IX in Patients with Acute Myocardial Infarction”,Arterioscler. Thromb. Vasc. Biol., 2000, 20, pp. 2489-2493.
Murakami, T., et al., “Evaluation of Factor Xla-α1-Antitrypsin in Plasma, a Contact Phase-Activated Coagulation Factor-Inhibitor Complex, in Patients With Coronary Artery Disease”,Arterioscler. Thromb. Vasc. Biol., 1995, 15, pp. 1107-1113.
Meijers, J.C.M., et al., “High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis”,N. Engl. J. Med., 2000, vol. 342, No. 10, pp. 696-701.
Walsh, P.N., “Platelets and Factor XI Bypass the Contact System of Blood Coagulation”,Thromb. Haemostasis. 82(2), pp. 234-242, 1999.
Colman, R. Contact Activation Pathway: Inflammatory, Fibrinolytic, Anticoagulant, Antiadhesive, and Antiangiogenic Activities,Hemostasis and thrombosis: basic principles and clinical practice, Lippincott Williams & Wilkins, 2001, pp. 103-122.
Schmaier, A.H., “Contact Activation”,Thrombosis and Hemorrhage, Williams&Wilkins, 1998, pp. 105-128.
ACS Registry No. 338410-51-8, 2005.
ACS Registry No. 554407-78-2, 2005.
ACS Registry No. 338410-59-6, 2005.
ACS Registry No. 430452-18-9, 2005.
ACS Registry No. 338410-55-2, 2005.
ACS Registry No. 338410-76-7, 2005.
ACS Registry No. 338410-56-3, 2005.
ACS Registry No. 338410-71-2, 2005.
Stanfield, M.K. et al: “Synthesis of phenistidine and derivatives”Journal of Organic Chemistry, 30(5) pp. 1548-1550 (1965).
Baettig U. et al., “The design and synthesis of thrombin inhibitors: analogues of MD805 containing non-polar surrogates for arginine at the P1 position” Bioorganic & Med. Chem. Letters, vol. 10, No. 14, Jul. 2000, p. 1563-1566.
Wazir et al., “Synthesis and anti-inflammatory activity of some substituted tetrazoles”, Journal of the Indian Chemical Society, 1991, India, vol. 68, No. 5, pp. 305-306.
Sheehan SM et al., “A four component coupling strategy for the synthesis of D-phenylglycinamide-derived non-covalent factor XA inhibitors”, Bioorganic * Med. Chem. Letters, vol. 13, No. 14, pp. 2255-2259, 2003.
U.S. Appl. No. 11/610,027, Pinto et al.
Ridker, Paul M, et al; “Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism”,N Engl J Med2003; 348:1425-34.
Becker, Richard C, “Anticoagulation and the Heart”,Journal of Thrombosis and Thrombolysis12(1), 41-52, 2001.
Albers, Gregory W, “Antithrombotic Therapy for Prevention and Treatment of Ischemic Stroke”,Journal of Thrombosis and Thrombolysis12(1), 19-22, 2001.
Turpie, Alexander G.G., “Optimizing Prophylaxis of Venous Thromboembolism”Seminars in Thrombosis and Hemostasis, vol. 28, Supplement 2, 2002, pp. 25-32.
Anderson Jr., Frederick A. et al., Prolonged Prophylaxis in Orthopedic Surgery: Insights from the United States,Seminars in Thrombosis and Hemostasis, vol. 28, supplement 3, 2002., pp. 43-46.
Heit, John A., “Venous Thromboembolism Epidemiology: Implications for Prevention and Management”,Seminars in Thrombosis and Hemostasis, vol. 28, Supplement 2, 2002., pp. 3-13.

Affiliated with

Also associated with

Rating

Five-membered heterocycles useful as serine protease inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Five-membered heterocycles useful as serine protease inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Five-membered heterocycles useful as serine protease inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4047128